Clinical trial
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
NCT03091192 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- July 25, 2017
- Completion date
- December 31, 2026
- Enrollment
- 60 (actual)
- Sites
- 59
Conditions
As the registry lists them; a condition with its own page is linked.
carcinoma, carcinoma, renal cell, enzyme inhibitors, kidney diseases, kidney neoplasms, neoplasms by site, protein kinase inhibitors, urologic neoplasms